Total Funding
53
60
Total FundingDebt Financing raised
Growth Score
2 pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
47209
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Daniel Geffken: Interim Chief Financial OfficerPast Role: CalciMedica, Interim Chief Financial Officer- Randy Watnick: Co-Founder
About the Company
Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types of cancer and improve the lives of patients. The company building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment
(TIME). They plan to commence multiple combination studies to evaluate VT1021 in combination with chemotherapies and/or anti-PD-1 antibodies.
The company was established in 2011 and is headquartered in Cambridge, Massachusetts.
Women Founded
